8-K current report · filed Nov 4, 2026

NEOGEN CORP (NEOG) 8-K Current Report: November 4, 2026

Item 8.01NEOG overview

Short answer

NEOGEN CORP (NEOG) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 8.01 (Other Events). Genomics sale to Zoetis remains pending, subject to regulatory approvals and customary closing conditions.

NEOGEN CORP 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • Genomics sale to Zoetis remains pending, subject to regulatory approvals and customary closing conditions
  • ACCC and NZCC reviews continue, extending expected regulatory clearance to early 2027
  • Zoetis offered to divest certain Australian assets to address competition concerns
  • Closing delay prolongs uncertainty around proceeds, strategic separation and Neogen’s post-sale business profile

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other NEOGEN CORP 8-K filings

Get the next NEOG 8-K as it lands

Follow NEOG for push alerts, or ask the research agent what this filing means.